Logo image of TRVN

TREVENA INC (TRVN) Stock Fundamental Analysis

NASDAQ:TRVN - Nasdaq - US89532E2081 - Common Stock - Currency: USD

2.5  -2.11 (-45.71%)

After market: 2.39 -0.11 (-4.4%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TRVN. TRVN was compared to 567 industry peers in the Biotechnology industry. TRVN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TRVN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TRVN had negative earnings in the past year.
TRVN had a negative operating cash flow in the past year.
TRVN had negative earnings in each of the past 5 years.
In the past 5 years TRVN always reported negative operating cash flow.
TRVN Yearly Net Income VS EBIT VS OCF VS FCFTRVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

TRVN's Return On Assets of -264.95% is on the low side compared to the rest of the industry. TRVN is outperformed by 94.16% of its industry peers.
Industry RankSector Rank
ROA -264.95%
ROE N/A
ROIC N/A
ROA(3y)-91.28%
ROA(5y)-69.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRVN Yearly ROA, ROE, ROICTRVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

TRVN's Gross Margin of 44.36% is fine compared to the rest of the industry. TRVN outperforms 78.76% of its industry peers.
In the last couple of years the Gross Margin of TRVN has declined.
TRVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.92%
GM growth 5YN/A
TRVN Yearly Profit, Operating, Gross MarginsTRVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K

More info and screens

3

2. Health

2.1 Basic Checks

TRVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
TRVN has less shares outstanding than it did 1 year ago.
TRVN has less shares outstanding than it did 5 years ago.
TRVN has a worse debt/assets ratio than last year.
TRVN Yearly Shares OutstandingTRVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
TRVN Yearly Total Debt VS Total AssetsTRVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

TRVN has an Altman-Z score of -44.49. This is a bad value and indicates that TRVN is not financially healthy and even has some risk of bankruptcy.
TRVN's Altman-Z score of -44.49 is on the low side compared to the rest of the industry. TRVN is outperformed by 93.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.49
ROIC/WACCN/A
WACC3.98%
TRVN Yearly LT Debt VS Equity VS FCFTRVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

TRVN has a Current Ratio of 3.46. This indicates that TRVN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.46, TRVN is doing worse than 60.88% of the companies in the same industry.
TRVN has a Quick Ratio of 3.46. This indicates that TRVN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TRVN (3.46) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.46
TRVN Yearly Current Assets VS Current LiabilitesTRVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

TRVN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -265.62%.
TRVN shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.93%.
TRVN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.42% yearly.
EPS 1Y (TTM)-265.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.33%
Revenue 1Y (TTM)40.93%
Revenue growth 3Y0.59%
Revenue growth 5Y-11.42%
Sales Q2Q%-89.24%

3.2 Future

The Earnings Per Share is expected to grow by 49.93% on average over the next years. This is a very strong growth
Based on estimates for the next years, TRVN will show a very strong growth in Revenue. The Revenue will grow by 198.34% on average per year.
EPS Next Y-916.33%
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%
EPS Next 5Y49.93%
Revenue Next Year-95.22%
Revenue Next 2Y63.52%
Revenue Next 3Y-25.99%
Revenue Next 5Y198.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TRVN Yearly Revenue VS EstimatesTRVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 0 200M 400M 600M 800M 1B
TRVN Yearly EPS VS EstimatesTRVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TRVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRVN Price Earnings VS Forward Price EarningsTRVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRVN Per share dataTRVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A cheap valuation may be justified as TRVN's earnings are expected to decrease with -100.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%

More info and screens

0

5. Dividend

5.1 Amount

TRVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREVENA INC

NASDAQ:TRVN (10/7/2024, 8:23:32 PM)

After market: 2.39 -0.11 (-4.4%)

2.5

-2.11 (-45.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2024-08-08/bmo
Earnings (Next)11-12 2024-11-12/bmo
Inst Owners4.42%
Inst Owner Change0%
Ins Owners1065.78%
Ins Owner Change0%
Market Cap2.13M
Analysts82.5
Price Target102 (3980%)
Short Float %0.41%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.61%
Min EPS beat(2)24.91%
Max EPS beat(2)44.32%
EPS beat(4)2
Avg EPS beat(4)-95.1%
Min EPS beat(4)-275.05%
Max EPS beat(4)44.32%
EPS beat(8)5
Avg EPS beat(8)-33.77%
EPS beat(12)8
Avg EPS beat(12)-19.49%
EPS beat(16)10
Avg EPS beat(16)-15.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2400%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1998.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-2027.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1500%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-16.38
EYN/A
EPS(NY)-20.25
Fwd EYN/A
FCF(TTM)-37.1
FCFYN/A
OCF(TTM)-37.08
OCFYN/A
SpS4.29
BVpS-22.3
TBVpS-22.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -264.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.36%
FCFM N/A
ROA(3y)-91.28%
ROA(5y)-69.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.92%
GM growth 5YN/A
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.16%
Cap/Sales 0.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.46
Altman-Z -44.49
F-Score3
WACC3.98%
ROIC/WACCN/A
Cap/Depr(3y)8.27%
Cap/Depr(5y)6.21%
Cap/Sales(3y)3.99%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-265.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.33%
EPS Next Y-916.33%
EPS Next 2Y-154.34%
EPS Next 3Y-100.54%
EPS Next 5Y49.93%
Revenue 1Y (TTM)40.93%
Revenue growth 3Y0.59%
Revenue growth 5Y-11.42%
Sales Q2Q%-89.24%
Revenue Next Year-95.22%
Revenue Next 2Y63.52%
Revenue Next 3Y-25.99%
Revenue Next 5Y198.34%
EBIT growth 1Y-46.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.58%
OCF growth 3YN/A
OCF growth 5YN/A